Annexin A5: shifting from a diagnostic towards a therapeutic realm.
The surge in apoptosis research and the discovery of the phosphatidylserine binding properties of annexin A5 have propelled a tremendous interest in cell death detection technologies. In the past years, annexin A5 has evolved from an efficient assay for detection of apoptotic cells in vitro to an in vivo molecular imaging technology with potential clinical use. A second key discovery, the specific internalization properties of annexin A5, has opened the opportunity to use annexin A5 for therapeutic applications. Annexin A5-mediated internalization creates a novel therapeutic platform for targeted drug delivery and cell entry to treat various diseases, including cancer and cardiovascular disease.
Kenis
H
H
Cardiovascular Research Institute Maastricht, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands. h.kenis@bioch.unimaas.nl
Hofstra
L
L
Reutelingsperger
C P M
CP
D000818:Animals; D017304:Annexin A5 / Q000378:metabolism / Q000627:therapeutic use*; D017209:Apoptosis; D002318:Cardiovascular Diseases / Q000188:drug therapy; D016503:Drug Delivery Systems; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D010718:Phosphatidylserines / Q000378:metabolism
D017304:Annexin A5; D010718:Phosphatidylserines